Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Neurogene Says NGN-401 Gene Therapy For Rett Syndrome Has Been Selected To Participate In FDA Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program

Author: Benzinga Newsdesk | June 03, 2024 07:45am

As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401's development. Two dose levels of NGN-401 are being evaluated in a Phase 1/2 clinical trial.

Posted In: NGNE